Rules and reporting

1. The board shall adopt rules in accordance with chapter 17A to carry out the purposes of, and to enforce the provisions of, this subchapter. The rules shall include but not be limited to the development of procedures relating to: a. Identifying each patient about whom information is entered into the program. b. An electronic format for the submission of information from pharmacies and prescribing practitioners. c. A waiver to submit information in another format for a pharmacy or prescribing practitioner unable to submit information electronically. d. An application by a pharmacy or prescribing practitioner for an extension of time for transmitting information to the program. e. The submission by an authorized requestor of a request for information and a procedure for the verification of the identity of the requestor. f. Use by the board or advisory committee of the program request records required by section 124.553, subsection 2, to document and report statistical information. g. Including all schedule II, schedule III, and schedule IV controlled substances, schedule V controlled substances including when dispensed by a pharmacist without a prescription except for sales of pseudoephedrine that are reported to the real-time electronic repository, opioid antagonists, and other prescription substances that the advisory committee and board determine can be addictive or fatal if not taken under the proper care and direction of a prescribing practitioner. h. Access by a pharmacist or prescribing practitioner to information in the program pursuant to a written agreement with the board. i. The correction or deletion of erroneous information in the program. j. The issuance annually of a prescribing practitioner activity report compiled from information from the program pursuant to subsection 3. k. The establishment of thresholds or other criteria or measures to be used in identifying an at-risk patient as provided in section 124.553, subsection 1, paragraph “g”, and the targeted distribution of proactive notifications suggesting review of the patient’s prescription history. 2. Beginning February 1, 2021, and annually by February 1 thereafter, the board shall present to the general assembly and the governor a report prepared consistent with section 124.555, subsection 3, paragraph “d”, which shall include but not be limited to the following: a. The cost to the state of implementing and maintaining the program. b. Information from pharmacies, prescribing practitioners, the board, the advisory committee, and others regarding the benefits or detriments of the program. c. Information from pharmacies, prescribing practitioners, the board, the advisory committee, and others regarding the board’s effectiveness in providing information from the program. 3. a. Annually by February 1, the board shall electronically, and at as low a cost as possible, issue each prescribing practitioner who prescribed a controlled substance reported to the program as dispensed in the preceding calendar year in this state a prescribing practitioner activity report which shall include but not be limited to the following: 1. A summary of the prescribing practitioner’s history of prescribing controlled substances. 2. A comparison of the prescribing practitioner’s history of prescribing controlled substances with the history of other prescribing practitioners of the same profession or specialty. 3. The prescribing practitioner’s history of program use. 4. General patient risk factors. 5. Educational updates. 6. Other pertinent information identified by the board by rule. b. Information provided to a prescribing practitioner in a report required under this subsection is privileged and shall be kept confidential pursuant to section 124.553, subsection 3.